Healthcare Realty Trust Inc (HR) Stock News

HR Chief is launching the CXO Summit on 7-8 October 2026 in London, a flagship event for Chief Human Resources Officers and senior HR executives. The summit features three panel discussions covering workforce transformation, skills development, and AI-ready workforce strategies, with confirmed speakers from NHS England, SUEZ, WPP, Shoosmiths, and Virgin Unite. The event aims to connect HR leadership with cross-functional C-suite executives across multiple sectors.

Celcuity announced FDA approval of REVTORPYK (gedatolisib), the first pan-PI3K and mTORC1/2 inhibitor, for treating HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutations. In the Phase 3 VIKTORIA-1 trial, the drug reduced disease progression or death risk by 76% when combined with palbociclib and fulvestrant, and 67% with fulvestrant alone. Commercial launch is anticipated in late Q3 2026.

ANI Pharmaceuticals reported positive Phase 4 trial results for ILUVIEN (fluocinolone acetonide intravitreal implant) in treating chronic non-infectious uveitis affecting the posterior segment. The trial met both co-primary endpoints with statistically significant improvements in visual acuity (+3.6 letters) and central subfield thickness reduction (-157.5 microns) at 6 months. Safety profile was consistent with prior trials, with ocular hypertension (6%) and cataract (5%) as the most common adverse events.

Rosen Law Firm is reminding Phreesia, Inc. investors who purchased stock between May 8, 2025 and March 30, 2026 of the July 13, 2026 deadline to serve as lead plaintiff in a securities class action. The lawsuit alleges that Phreesia made false statements and concealed material facts regarding slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor damages.

Bernstein Liebhard LLP has announced an investigation into whether certain directors and officers of Phreesia, Inc. breached their fiduciary duties to the company. The investigation targets shareholders who purchased shares prior to May 8, 2025. The law firm is seeking affected shareholders to discuss their legal rights and options.

The Schall Law Firm is seeking investors who purchased Phreesia, Inc. securities between May 8, 2025 and March 30, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding its long-term growth outlook and fiscal year 2027 projections, particularly regarding pharmaceutical marketing commitments as a growth driver for its Network Solutions segment.

Rosen Law Firm is reminding investors in Phreesia, Inc. who purchased common stock between May 8, 2025 and March 30, 2026 of an important July 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Phreesia made false statements and concealed material negative facts regarding declining demand and reduced transparency in revenue sources, particularly in its network solutions segment. Investors who suffered losses exceeding $100,000 are encouraged to seek legal representation.

A securities class action lawsuit has been filed against Phreesia, Inc. for allegedly making false and misleading statements about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. Investors who purchased stock between May 8, 2025 and March 30, 2026 and suffered losses exceeding $100,000 are encouraged to join the class action before the July 13, 2026 lead plaintiff deadline.

A class action lawsuit has been filed against Phreesia Inc. for allegedly misleading investors about revenue growth projections and risks in its Network Solutions segment. The company announced significantly lowered fiscal 2027 revenue guidance on March 30, 2026, causing the stock to plummet 26.6%. The deadline to file a lead plaintiff motion is July 13, 2026.

Heathrow Finance PLC announced a EUR 350 million offering of 4-year senior secured notes with a stabilisation period from July 2, 2026 to August 7, 2026. BNP Paribas, Bank of America, ING, JP Morgan, Barclays, and National Bank of Australia are serving as stabilisation managers and may conduct market support activities during the offering period.

Quantum X Labs Inc. (Nasdaq: QXL) has successfully demonstrated its first fully all-optical Hemispherical Resonator Gyroscope (HRG) using optical excitation and readout instead of conventional electrostatic actuation. The technology eliminates electrode structures, reducing complexity, failure points, and electrical noise while providing intrinsic electrical isolation. The company plans to continue development toward deployable inertial measurement units for aerospace, defense, and autonomous transportation applications.

Rosen Law Firm is notifying investors in Phreesia, Roblox, and Zoetis of ongoing securities class action lawsuits. Phreesia investors who purchased stock between May 8, 2025 and March 30, 2026 are reminded of the July 13, 2026 lead plaintiff deadline. The lawsuit alleges that Phreesia made false statements regarding slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding inventory management, clinical trial status, and long-term growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the July 6-13, 2026 deadlines.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against multiple companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false or misleading statements regarding inventory management, clinical trial prospects, and growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status.

A class action lawsuit has been filed against Phreesia Inc. for allegedly misleading investors about revenue growth projections and risks in its Network Solutions segment. The company announced significantly lowered fiscal 2027 revenue guidance on March 30, 2026, causing the stock to plummet 26.6%. Investors who purchased shares between May 8, 2025 and March 30, 2026 can file a lead plaintiff motion by July 13, 2026.

The Gross Law Firm has announced a securities class action lawsuit against Phreesia, Inc. (PHR) on behalf of shareholders who purchased shares between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia made materially false and misleading statements while concealing adverse facts about slowing demand and weakened pharmaceutical marketing commitments. Following the company's announcement of significantly reduced revenue guidance on March 30, 2026, PHR stock declined approximately 27% from $11.41 to $8.38 per share. The deadline to seek lead plaintiff status is July 13, 2026.

Rosen Law Firm reminds Phreesia, Inc. (NYSE: PHR) investors of the July 13, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Phreesia made false or misleading statements regarding slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment, causing investor damages.

Rosen Law Firm reminds Phreesia, Inc. investors who purchased stock between May 8, 2025 and March 30, 2026 of the July 13, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Phreesia made false statements and concealed material facts regarding slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment.

Iran closes Strait of Hormuz over ceasefire violations - MEHR  Reuters

A federal securities class action has been filed against Phreesia, Inc. (NYSE: PHR) alleging that the company and its executives made false and misleading statements about growth opportunities while concealing slowing demand and weakening pharmaceutical marketing commitments. After Phreesia announced significantly reduced revenue guidance on March 30, 2026, the stock price fell approximately 27% from $11.41 to $8.38 per share. Investors who purchased PHR stock between May 8, 2025 and March 30, 2026 have until July 13, 2026 to seek lead plaintiff appointment.

Rosen Law Firm is notifying Phreesia, Inc. investors who purchased stock between May 8, 2025 and March 30, 2026 of an important July 13, 2026 deadline to serve as lead plaintiff in a securities class action. The lawsuit alleges that Phreesia made false statements and concealed material facts regarding slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor damages.

Holzer & Holzer, LLC announces lead plaintiff deadlines for shareholder class action lawsuits against three companies. Phreesia faces allegations of false statements regarding long-term growth outlook (deadline July 13, 2026). AeroVironment is accused of misrepresenting its competitive landscape (deadline July 27, 2026). Lucid Group faces claims about false statements regarding manufacturing and delivery capabilities (deadline July 28, 2026). Investors who purchased shares during the alleged fraud periods and suffered losses are encouraged to contact the firm.

MEXICO CITY, June 18, 2026.- Swell , a leading Mexican credit provider, has had its BBB- rating reaffirmed with a Stable Outlook by HR Ratings for a second consecutive year. HR Ratings announced the decision on June 17, 2026. Swell is a Mexican non-bank financial institution focused on financing small and medium-sized enterprises (SMEs). The agency also affirmed Swell's HR3 short-term rating, citing improvements in capitalization, profitability, financial efficiency, and funding diversification, and a capitalization ratio of 37.9%, supported by earnings generation and operational efficiencies. It also cited a 3.4% return on assets (ROA), tied to a wider net financial margin, lower funding costs, and the firm's portfolio recovery strategy. "Earning this rating for a second consecutive year matters because it reflects consistency, not a single moment in time. It tells us the foundations we have been building -operational discipline, strong corporate governance, and prudent risk management- are holding up year after year," said Ethel Mora, who became CEO of Swell in 2023. "This year's reaffirmation conveys a validation that our Strategic Plan, coupled with ... Full story available on Benzinga.com

Pomerantz LLP is investigating potential securities fraud at Aether Holdings (ATHR), following a July 2025 short report by BMF Reports alleging fake filings, insider enrichment, lock-up violations, and undisclosed dealings. The allegations included concerns about a subsidiary acquisition with minimal business fundamentals. Aether's stock fell 23.95% on the report's publication.

A class action lawsuit has been filed against Phreesia, Inc. (NYSE:PHR) in the U.S. District Court for the District of Delaware, alleging that the company and its executives made false or misleading statements regarding revenue visibility. The company significantly reduced its FY 2027 revenue guidance from $545-$559 million to $510-$520 million on March 30, 2026, citing weaker pharmaceutical-marketing commitments and reduced visibility in its Network Solutions segment—risks that were not disclosed during the December 8, 2025 earnings call. The stock fell 21-28% following the revised outlook.

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies. Phreesia Inc. faces allegations of misrepresenting growth projections, Sportradar Group AG is accused of working with black-market gambling operators while claiming compliance, Commvault Systems Inc. allegedly failed to properly account for sales type impacts on ARR growth, and Veritone Inc. is charged with revenue misclassification and deficient internal controls. Investors have until mid-July 2026 to file lead plaintiff motions.

Rosen Law Firm is notifying investors in Phreesia, Inc., Babcock & Wilcox Enterprises, Inc., and TruBridge, Inc. of ongoing securities class action lawsuits. Phreesia investors have until July 13, 2026 to serve as lead plaintiff. The lawsuit alleges Phreesia made false statements about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Phreesia, Inc. The lawsuit alleges that defendants made false and misleading statements regarding slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in the Network Solutions segment. The lead plaintiff deadline is July 13, 2026.

A class action lawsuit has been filed against Phreesia, Inc. (NYSE:PHR) for allegedly making false and misleading statements regarding its financial performance. The company failed to disclose slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. On March 30, 2026, Phreesia reduced its FY 2027 revenue guidance by $35-49 million to $510-520 million, citing weaker pharmaceutical-marketing commitments that had not been mentioned during the December 2025 earnings call. The stock fell 21-28% following the revised outlook. Investors who purchased shares between May 8, 2025, and March 30, 2026, can participate in the lawsuit with a deadline of July 13, 2026, to apply as lead plaintiff.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Phreesia Inc., Sportradar Group AG, Commvault Systems Inc., and Veritone Inc. Investors have until mid-July 2026 to file lead plaintiff motions. The complaints allege various forms of misrepresentation including false growth projections, undisclosed compliance violations, misleading revenue guidance, and accounting irregularities.